propyl N-[4-[(5-chlorothiophen-2-yl)methylamino]phenyl]carbamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: propyl N-[4-[(5-chlorothiophen-2-yl)methylamino]phenyl]carbamate
• 化学式: C₁₅H₁₇ClN₂O₂S
• 分子量: 324.8
• InChiKey: AANRTTWSJLIBNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  78.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Inducible nitric oxide synthase dimerization inhibitors
  申请人：Gahman C. Timothy

  公开号：US20060116515A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR 4 , N, NR 4 , S, and O; U is selected from the group consisting of CR 10 and N; V is selected from the group consisting of CR 4 and N; W and W′ are independently selected from the group consisting of CH 2 , CR 7 R 8 , NR 9 , O, N(O), S(O) q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

  本发明涉及化合物和方法，用作一氧化氮合酶的抑制剂。本发明的某些化合物具有以下结构式： 其中T、X和Y分别选自CR 4 、N、NR 4 、S和O组成的群；U选自CR 10 和N组成的群；V选自CR 4 和N组成的群；W和W′分别选自CH 2 、CR 7 R 8 、NR 9 、O、N(O)、S(O) q 和C(O)组成的群；n、m和p分别是从0到5的整数；q为0、1或2；其他取代基如本文所定义。本发明的其他化合物具有如本文所定义的结构式。本文还公开了包含本发明化合物的药物组合物。
• [EN] SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES<br/>[FR] DERIVES DE PARA-DIAMINOBENZENE SUBSTITUES
  申请人：LUNDBECK & CO AS H

  公开号：WO2004082677A1

  公开（公告）日：2004-09-30

  The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

  本发明涉及通式I的苯胺衍生物或其药学上可接受的盐及其用途。
• Substituted p-diaminobenzene derivatives
  申请人：Khanzhin Nikolay

  公开号：US20060183791A1

  公开（公告）日：2006-08-17

  The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

  本发明涉及一般式I的苯胺衍生物或其药学上可接受的盐及其用途。
• Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia
  申请人：H. Lundbeck A/S

  公开号：EP2554162A1

  公开（公告）日：2013-02-06

  The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of selective KCNQ potassium channel openers for the preparation of a pharmaceutical composition for treating or reducing the symptoms of schizophrenia and related symptoms, disorders and diseases. Furthermore the invention relates to a method of screening for a compound, which is a selective KCNQ potassium channel opener and which is capable of having an anti-psychotic potential.

  本发明涉及一种治疗或减轻精神分裂症症状的新方法，所述方法包括向有需要的宿主施用有效量的能够选择性地增加通过 KCNQ 钾通道的离子流的化合物。此外，本发明还涉及选择性 KCNQ 钾通道开放剂用于制备治疗或减轻精神分裂症症状及相关症状、紊乱和疾病的药物组合物。此外，本发明还涉及一种筛选化合物的方法，该化合物是一种选择性 KCNQ 钾通道开启剂，具有抗精神病的潜力。
• EP1613303A1
  申请人：——

  公开号：EP1613303A1

  公开（公告）日：2006-01-11